We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions -- United States, March-August 2021.
- Authors
Self, Wesley H.; Tenforde, Mark W.; Rhoads, Jillian P.; Gaglani, Manjusha; Ginde, Adit A.; Douin, David J.; Olson, Samantha M.; Talbot, H. Keipp; Casey, Jonathan D.; Mohr, Nicholas M.; Zepeski, Anne; McNeal, Tresa; Ghamande, Shekhar; Gibbs, Kevin W.; Files, D. Clark; Hager, David N.; Shehu, Arber; Prekker, Matthew E.; Erickson, Heidi L.; Gong, Michelle N.
- Abstract
The article compares the effectiveness of three COVID-19 vaccines, including Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson)—in preventing hospitalizations among adults without immunocompromising conditions in the United States from March to August 2021. The study shows that the two-dose mRNA vaccines, Moderna and Pfizer-BioNTech, provided a higher level of protection against COVID-19 hospitalizations compared to the single-dose Janssen vaccine.
- Subjects
UNITED States; COVID-19 vaccines; VACCINE effectiveness; COVID-19 testing; IMMUNOCOMPROMISED patients
- Publication
MMWR: Morbidity & Mortality Weekly Report, 2021, Vol 70, Issue 38, p1337
- ISSN
0149-2195
- Publication type
Article
- DOI
10.15585/mmwr.mm7038e1